We provide you with 20 years of free, institutional-grade data for ETNB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ETNB. Explore the full financial landscape of ETNB stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-08 | 1785173 | ETNB | 10-Q | Url |
| 2025-05-02 | 1785173 | ETNB | 10-Q | Url |
| 2025-02-27 | 1785173 | ETNB | 10-K | Url |
| 2024-11-07 | 1785173 | ETNB | 10-Q | Url |
| 2024-08-05 | 1785173 | ETNB | 10-Q | Url |
| 2024-05-09 | 1785173 | ETNB | 10-Q | Url |
| 2024-03-01 | 1785173 | ETNB | 10-K | Url |
| 2023-11-09 | 1785173 | ETNB | 10-Q | Url |
| 2023-08-09 | 1785173 | ETNB | 10-Q | Url |
| 2023-05-08 | 1785173 | ETNB | 10-Q | Url |
| 2023-03-15 | 1785173 | ETNB | 10-K | Url |
| 2022-11-10 | 1785173 | ETNB | 10-Q | Url |
| 2022-08-11 | 1785173 | ETNB | 10-Q | Url |
| 2022-05-12 | 1785173 | ETNB | 10-Q | Url |
| 2022-03-24 | 1785173 | ETNB | 10-K | Url |
| 2021-11-12 | 1785173 | ETNB | 10-Q | Url |
| 2021-08-13 | 1785173 | ETNB | 10-Q | Url |
| 2021-05-14 | 1785173 | ETNB | 10-Q | Url |
| 2021-03-25 | 1785173 | ETNB | 10-K | Url |
| 2020-11-13 | 1785173 | ETNB | 10-Q | Url |
| 2020-09-14 | 1785173 | ETNB | S-1 | Url |
| 2020-08-13 | 1785173 | ETNB | 10-Q | Url |
| 2020-07-06 | 1785173 | ETNB | S-1 | Url |
| 2020-05-13 | 1785173 | ETNB | 10-Q | Url |
| 2020-03-18 | 1785173 | ETNB | 10-K | Url |
| 2019-12-18 | 1785173 | ETNB | 10-Q | Url |
| 2019-10-11 | 1785173 | ETNB | S-1 | Url |
89bio, Inc(NASDAQ:ETNB) 
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalc...
Website: http://www.89bio.com
Founded: 2018
IPO Price: $16 (Nov 11, 2019)
Full Time Employees: 25
CEO: Rohan Palekar
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about ETNB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.